Solid Biosciences Inc.

SLDB ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $59.9M $80.2M $74.0M $155.4M $119.1M $154.7M $76.0M $86.4M
Accounts Receivable
Inventory
Total Current Assets $205.5M $157.3M $129.7M $219.6M $222.6M $158.9M $86.3M $128.6M
Property, Plant & Equipment $4.2M $4.7M $6.6M $9.7M $6.5M $8.2M $11.6M $10.4M
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $232.5M $188.7M $164.9M $260.3M $232.4M $171.2M $103.5M $139.6M
Liabilities
Accounts Payable $3.2M $4.2M $2.0M $3.2M $4.5M $3.3M $7.1M $3.7M
Total Current Liabilities $33.5M $30.3M $14.5M $22.5M $23.6M $24.5M $18.3M $12.5M
Long-Term Debt
Total Liabilities $52.5M $51.4M $38.5M $48.6M $24.2M $39.1M $23.4M $14.4M
Stockholders' Equity
Retained Earnings $-957.8M $-783.5M $-658.8M $-562.7M $-476.8M $-404.6M $-316.3M $-199.1M
Total Stockholders' Equity $180.0M $137.2M $126.5M $211.7M $208.2M $132.1M $80.0M $125.2M
← Newer Page 1 of 2 Older →